Lurie Children's Hospital of Chicago Developmental Therapeutics

Chicago, Illinois 60611

0 studies enrolling now · 6 studies all time

What they study most

Hematologic Malignancies, PI3K Pathway Activated Tumors, PTCH1 or SMO Activated Solid and Hematologic Tumors, Solid Tumor, Solid Tumor and Hematologic Malignancies, Tumor Pathway Activations Inhibited by Dovitinib

Studies at this site

• LGX818 for Patients With BRAFV600 Mutated Tumors — Stopped early
• MEK162 for Patients With RAS/RAF/MEK Activated Tumors — Completed
• BGJ398 for Patients With Tumors With FGFR Genetic Alterations — Stopped early
• BKM120 for Patients With PI3K-activated Tumors — Completed
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib — Completed
• LDE225 for Patients With PTCH1 or SMO Mutated Tumors — Stopped early